NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference CallGlobeNewsWire • 04/15/21
NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 01/29/21
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference CallGlobeNewsWire • 01/22/21
NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/22/20
NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference CallGlobeNewsWire • 10/15/20
NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief DeviceGlobeNewsWire • 09/22/20
NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable TechnologyGlobeNewsWire • 09/21/20
NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual ConferenceGlobeNewsWire • 09/04/20
NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy SeverityGlobeNewsWire • 09/01/20
NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical TrialGlobeNewsWire • 08/20/20
NeuroMetrix's (NURO) CEO Shai Gozani on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/23/20
NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference CallGlobeNewsWire • 07/16/20
NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief DeviceGlobeNewsWire • 06/10/20
NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/23/20
NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for FibromyalgiaGlobeNewsWire • 04/16/20
NeuroMetrix Provides Quell® Technology Commercial Strategy and Pipeline UpdateGlobeNewsWire • 03/11/20